Bococizumab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBococizumab
Drug Alias NameBococizumabum波西组单抗伯考赛珠单抗PF-04950615RN-316 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipidemias +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[42] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of California San FranciscoPfizer IncPfizer Manufacturing Belgium Nv +[4] 
Active IndicationsN/A
Inactive IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipidemias +[7] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG